BioGaia Oral Health Probiotic to be Launched in Three New Markets

796bbc43-817d-429e-ba64-74f3e3384348articleimage.jpg

24 Apr 2017 --- BioGaia has signed three new exclusive agreements for Prodentis, its oral food supplement that contains a natural lactic acid bacteria, Lactobacillus reuteri Prodentis. The new agreements will see the product launched in Canada, Vietnam and the Philippines.

Hansamed Ltd will manage the sales in Canada, BioCulture sales in the Philippines and with MTC Pharma Co Ltd sales in Vietnam.

All three distribution partners will sell Prodentis under the BioGaia brand and plan to launch during 2017. Most of BioGaia’s partners selling Prodentis focus on medical marketing, and this will also be the business model in the three new countries.

BioGaia’s oral health products contain the patented probiotic Lactobacillus reuteri Prodentis, which has shown positive effects on above all gingivitis and periodontal disease in close to 30 clinical studies.

The portfolio consists of lozenges and chewing gum for consumers as well as oil drops for professional use.

Today BioGaia's oral health products are sold in more than 20 countries worldwide, and the company states that the strategy is to continue to expand this global network.

“We have a very strong focus on developing our oral health business and our sales of Prodentis, for which we have strong clinical evidence,” says Axel Sjöblad, Managing Director, BioGaia. “I am therefore very happy that we have signed another three agreements with solid partners in both Canada and Asia.”

The company adds that as the market for probiotics in oral health grows, BioGaia sees a large potential for Prodentis within the coming years.

To contact our editorial team please email us at editorial@cnsmedia.com

RELATED ARTICLES
Homepicture

Healthier indulgence: Beneo to showcase toffees with isomaltulose

25 Jan 2019 At this year’s ISM trade fair in Cologne, ...

Homepicture

“Landmark day”: GSK and Pfizer to form new Consumer Healthcare Joint Venture

19 Dec 2018 Pharma heavyweights GlaxoSmithKline plc (GSK) ...